Pharmaceutical Market Europe • Octber 2025 • 3

COMMENT

Navigating the ‘Patient Metro’

In our cover story this month, Danny Buckland looks at navigating the ‘Patient Metro’ – a journey full of insights, and why the key to unravelling its potential is to focus on the intersections where journeys are made or broken.

As Danny says: The patient journey rarely runs along accepted lines and timetables, but all have points where conditions and treatments intersect with clinical and personal experiences. They don’t lend themselves to an app or pocket-sized map, but these ‘insight stops’ are everywhere along the line from diagnosis to discharge, and routine check-ups to meetings with consultants.

“Recognising and understanding that these moments, and their personal and logistical mechanics, are the busiest, and potentially most rewarding, sectors of modern healthcare, the junction of industry commitment, technology and HCP engagement is putting patient insights on a fast track to improve outcomes.” Read more on page 28.

In this issue we also have an article from Henrik Zetterberg from the University of Gothenburg and UCL on the three non-negotiable pillars of Alzheimer’s blood testing and why sensitivity, access and education will define scalable Alzheimer’s diagnostics. As Henrik says: “Projections estimate that an alarming 153 million people will be living with Alzheimer’s or related dementias by 2050. Sensitivity and accuracy are essential in Alzheimer’s blood testing because early and reliable detection is vital for meaningful intervention.” Find out more on page 16.

Another highlight of this issue is an article on page 20 heralding a new advent of clinical pathway management. With over half of all phase 3 clinical trials failing, with an estimated cost of between $800m to $1.4bn per drug failure, Jon Gibbins and Chris Jones explain why platelet functionality analysis could pave the way to improving drug asset selection and de-risking clinical trials.

Our next issue, in November 2025, will look at the important role of medical affairs. If you would like to make your voice heard on this topic, please get in touch at sales@pmlive.com

I hope you enjoy this issue!

Image

Iona Everson
Group Managing Editor

Image

Keep up to date with the latest developments in the UK and global healthcare marketplace – sign up to daily or weekly news alerts and fortnightly or monthly bulletins on specific topics at  www.pmlive.com/register

Image

THE TEAM
Editorial:
Group Managing Editor
Iona Everson

Deputy Editor
Emily Kimber


Sales:
Business Director
Tara Lovegrove

Executive Director
Karl Equi


EDITORIAL ADVISORY BOARD
Philip Atkinson
Founder of Hive-Logic, Lifescience Transformation

Uday Bose
Corporate vice president, head of global marketing oncology, Boehringer Ingelheim

Dr Luc Hermans
VP commercial planning and operations Europe, Asia, Middle East, Gilead Sciences

Stefan Janssens
President EMEA, Cegedim Dendrite

John Morris
Partner, KPMG

Paul Pay
Chief business development officer, Norgine

Mark Rothera
Chief executive officer, Orchard Therapeutics

Ian Talmage
Senior vice president, global marketing, general medicine, Bayer Pharmaceuticals

PUBLISHED BY
PMGroup Worldwide Ltd
44 Maiden Lane
Covent Garden
London
WC2E 7LN


CONTACT US
General enquiries: info@pmlive.com
Editorial: editor@pmlive.com
Advertising: sales@pmlive.com
Subscriptions: subscriptions@pmlive.com

Views expressed by the contributors do not necessarily represent those of the publisher, editor or staff.

© 2025 PMGroup
All rights reserved. No part of this publication may be copied, reproduced, transmitted, photocopied, recorded or stored on any retrieval system without the prior written consent of the publishers.

The magazine is also available at the following subscription rates: £120 UK, £180 Europe, £210 RoW

Image